Detalhe da pesquisa
1.
Trial of Spesolimab for Generalized Pustular Psoriasis.
N Engl J Med
; 385(26): 2431-2440, 2021 12 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34936739
2.
Generalized pustular psoriasis: A nationwide population-based study using the National Health Data System in France.
J Eur Acad Dermatol Venereol
; 2024 Feb 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38404163
3.
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
J Eur Acad Dermatol Venereol
; 38(5): 864-872, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38179809
4.
Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus.
Exp Dermatol
; 32(6): 859-868, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36922453
5.
Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
Br J Dermatol
; 188(5): 610-617, 2023 04 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36763806
6.
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
J Am Acad Dermatol
; 89(1): 36-44, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36870370
7.
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares.
Dermatology
; 239(3): 345-354, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36796336
8.
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.
Clin Exp Dermatol
; 48(11): 1238-1246, 2023 Oct 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37409606
9.
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).
J Eur Acad Dermatol Venereol
; 37(7): 1327-1335, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-36854864
10.
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
J Allergy Clin Immunol
; 149(4): 1402-1412, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34678325
11.
A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study.
Dermatology
; 238(4): 630-639, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34883480
12.
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
Acta Derm Venereol
; 102: adv00665, 2022 Mar 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34806759
13.
Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood.
Acta Derm Venereol
; 102: adv00733, 2022 Jun 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35506359
14.
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
J Allergy Clin Immunol
; 147(1): 60-71, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33075408
15.
Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts.
Dermatology
; 237(5): 748-758, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33503635
16.
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Dermatology
; 237(3): 338-346, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33535213
17.
Pustular Psoriasis and Associated Musculoskeletal Disorders.
J Rheumatol Suppl
; 97: 34-38, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34074664
18.
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
J Am Acad Dermatol
; 82(2): 352-359, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31175909
19.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet
; 392(10148): 650-661, 2018 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-30097359
20.
Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome.
Exp Dermatol
; 28(10): 1114-1117, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28603914